The molecular basis of disease variability among cystic fibrosis patients carrying the 3849+10 kb C-->T mutation.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Genomics

• Publication date

  1998-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1006/GENO.1998.5517PMID 9799593
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Increased proportion of exon 9 alternatively spliced CFTR transcripts in vas deferens compared with nasal epithelial cells.

  1997cited by this paper
• Higher proportion of intact exon 9 CFTR mRNA in nasal epithelium compared with vas deferens.

  1997cited by this paper
• The molecular basis of partial penetrance of splicing mutations in cystic fibrosis.

  1997cited by this paper
• A cystic fibrosis transmembrane conductance regulator splice variant with partial penetrance associated with variable cystic fibrosis presentations.

  1997cited by this paper
• Mutations in the sulonylurea receptor gene are associated with familial hyperinsulinism in Ashkenazi Jews.

  1996cited by this paper
• Modulation of disease severity in cystic fibrosis transmembrane conductance regulator deficient mice by a secondary genetic factor

  1996cited by this paper
• A novel donor splice site in intron 11 of the CFTR gene, created by mutation 1811+1.6kbA-->G, produces a new exon: high frequency in Spanish cystic fibrosis chromosomes and association with severe phenotype.

  1995cited by this paper
• The relationship between genotype and phenotype in cystic fibrosis.

  1995cited by this paper
• Regulation of alternative splicing in vivo by overexpression of antagonistic splicing factors.

  1994cited by this paper
• Similar levels of mRNA from the W1282X and the delta F508 cystic fibrosis alleles, in nasal epithelial cells.

  1994cited by this paper
• A novel bipartite splicing enhancer modulates the differential processing of the human fibronectin EDA exon.

  1994cited by this paper
• A novel mutation in the cystic fibrosis gene in patients with pulmonary disease but normal sweat chloride concentrations.

  1994cited by this paper
• Maintenance of an open reading frame as an additional level of scrutiny during splice site selection

  1994cited by this paper
• Correct splicing despite mutation of the invariant first nucleotide of a 5' splice site: a possible basis for disparate clinical phenotypes in siblings with adenosine deaminase deficiency.

  1994cited by this paper
• Extended haplotype analysis of cystic fibrosis mutations and its implications for the selective advantage hypothesis

  1993cited by this paper
• Mild cystic fibrosis and normal or borderline sweat test in patients with the 3849 + 10 kb C-->T mutation.

  1993cited by this paper
• Genetic basis of variable exon 9 skipping in cystic fibrosis transmembrane conductance regulator mRNA

  1993cited by this paper
• An unusual splicing mutation in the HEXB gene is associated with dramatically different phenotypes in patients from different racial backgrounds.

  1992cited by this paper
• Lymphocyte mRNA as a resource for detection of mutations and polymorphisms in the CF gene.

  1991cited by this paper
• Identification of the cystic fibrosis gene: genetic analysis.

  1989cited by this paper
• Leukocyte adhesion deficiency. Aberrant splicing of a conserved integrin sequence causes a moderate deficiency phenotype.

  1989cited by this paper
• Alternative splicing in the control of gene expression.

  1989cited by this paper
• DNA marker haplotype association with pancreatic sufficiency in cystic fibrosis.

  1989cited by this paper
• The Metabolic basis of inherited disease

  1989cited by this paper
• Structure and Function of Major and Minor Small Nuclear Ribonucleoprotein Particles

  1988cited by this paper
• Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease.

  1979cited by this paper

• Intestinal organoids as a platform for functional evaluation of ASO-mediated splicing modulation in cystic fibrosis.

  2026cites this paper
• CFTR activity in nasal potential difference of adults with idiopathic bronchiectasis.

  2026cites this paper
• Functional Consequences of CFTR Interactions in Cystic Fibrosis

  2024cites this paper
• Rectal organoid morphology analysis (ROMA) as a novel physiological assay for diagnostic classification in cystic fibrosis

  2024cites this paper
• Elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and rare mutations

  2024cites this paper
• Explanations for the discrepancy between variant frequency and homozygous disease occurrence: Lessons from Ashkenazi Jewish data.

  2023cites this paper
• Molecular and functional correction of a deep intronic splicing mutation in CFTR by CRISPR-Cas9 gene editing

  2023cites this paper
• Splicing mutations in the CFTR gene as therapeutic targets

  2022cites this paper
• Non-Modulator Therapies: Developing a Therapy for Every Cystic Fibrosis Patient.

  2022cites this paper
• One Size Does Not Fit All: The Past, Present and Future of Cystic Fibrosis Causal Therapies

  2022cites this paper
• Heterogeneous spectrum of CFTR gene mutations in Chinese patients with CAVD and the dilemma of genetic blocking strategy.

  2022cites this paper
• Oligonucleotide-based therapies for cystic fibrosis.

  2022cites this paper
• ECFS standards of care on CFTR-related disorders: Diagnostic criteria of CFTR dysfunction.

  2022cites this paper
• Antisense oligonucleotide-based drug development for Cystic Fibrosis patients carrying the 3849 + 10 kb C-to-T splicing mutation

  2021cites this paper
• VJ Segment Usage of TCR-Beta Repertoire in Monozygotic Cystic Fibrosis Twins

  2021cites this paper
• Emerging technologies for cystic fibrosis transmembrane conductance regulator restoration in all people with CF

  2020cites this paper
• EPG5 c.1007A > G mutation in a sibling pair with rapidly progressing Vici syndrome

  2020cites this paper
• Incomplete cryptic splicing by an intronic mutation of OCRL in patients with partial phenotypes of Lowe syndrome

  2020cites this paper
• Antisense oligonucleotide-mediated correction of CFTR splicing improves chloride secretion in cystic fibrosis patient-derived bronchial epithelial cells

  2020cites this paper
• Two sides of the same medal: Noncoding mutations reveal new pathological mechanisms and insights into the regulation of gene expression

  2020cites this paper
• Ivacaftor in People with Cystic Fibrosis and a 3849+10kb C→T or D1152H Residual Function Mutation

  2020cites this paper
• Mechanism-Based Personalized Medicine for Cystic Fibrosis by Suppressing Pseudo Exon Inclusion.

  2020cites this paper
• Functional characterization and phenotypic spectrum of three recurrent disease-causing deep intronic variants of the CFTR gene.

  2019cites this paper
• Symposium Summaries

  2018cites this paper
• Rôle des miARN et des ARE-BP dans la mucoviscidose

  2018cites this paper
• Advanced cell‐based modeling of the royal disease: characterization of the mutated F9 mRNA

  2017cites this paper
• The suppression of premature termination codons and the repair of splicing mutations in CFTR

  2017cites this paper
• In vivo and in vitro ivacaftor response in cystic fibrosis patients with residual CFTR function: N‐of‐1 studies

  2017cites this paper
• Cas9/gRNA targeted excision of cystic fibrosis-causing deep-intronic splicing mutations restores normal splicing of CFTR mRNA

  2017cites this paper
• Symposium Summaries

  2016cites this paper
• The roles of RNA processing in translating genotype to phenotype

  2016cites this paper
• Genotypes and Phenotypes in Cystic Fibrosis and Cystic Fibrosis Transmembrane Regulator–Related Disorders

  2015cites this paper
• Symposium Session Summaries

  2014cites this paper
• Clinical and mutation profile of children with cystic fibrosis in Jammu and Kashmir

  2014cites this paper
• Where genotype is not predictive of phenotype: towards an understanding of the molecular basis of reduced penetrance in human inherited disease

  2013cites this paper
• Assessing the residual CFTR gene expression in human nasal epithelium cells bearing CFTR splicing mutations causing cystic fibrosis

  2013cites this paper
• Defective CFTR Expression and Function Are Detectable in Blood Monocytes: Development of a New Blood Test for Cystic Fibrosis

  2011cites this paper
• Aberrant PKD2 splicing due to a presumed novel missense mutation in autosomal‐dominant polycystic kidney disease

  2011cites this paper
• Characterization of a Disease-associated Mutation Affecting a Putative Splicing Regulatory Element in Intron 6b of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Gene*

  2009cites this paper
• UvA-DARE ( Digital Academic Repository ) Alternative splicing of thyroid hormone receptor alpha transcripts during health and disease

  2009cites this paper
• New Genetic and Pharmacological Treatments for Cystic Fibrosis

  2009cites this paper
• Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice.

  2008cites this paper
• Restoration of the CFTR function by splicing modulation

  2007cites this paper
• Splicing in disease: disruption of the splicing code and the decoding machinery

  2007cites this paper
• Role of hypoxia in epithelial gene regulation

  2007cites this paper
• Cystic Fibrosis Transmembrane Regulator Protein Mutations

  2007cites this paper
• Constitutional high expression of an APC mRNA isoform in a subset of attenuated familial adenomatous polyposis patients

  2007cites this paper
• Aberrant splicing is a common mutational mechanism in MKS1, a key player in Meckel‐Gruber syndrome

  2007cites this paper
• Splicing modulation as a modifier of the CFTR function.

  2006cites this paper
• Spontaneous rescue from cystic fibrosis in a mouse model

  2006cites this paper
• NF1 mutation rather than individual genetic variability is the main determinant of the NF1‐transcriptional profile of mutations affecting splicing

  2006cites this paper
• A 96-well formatted method for exon and exon/intron boundary full sequencing of the CFTR gene.

  2006cites this paper
• CYSTIC FIBROSIS | Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Gene

  2006cites this paper
• DE NOVO CATIONIC ANTIMICROBIAL PEPTIDES AS THERAPEUTICS AGAINST PSEUDOMONAS AERUGINOSA

  2006cites this paper
• Genotype-Phenotype Correlations in Cystic Fibrosis

  2006cites this paper
• Processing of CFTR: Traversing the cellular maze—How much CFTR needs to go through to avoid cystic fibrosis?

  2005cites this paper
• The clinical significance of a common, functional, X-linked angiotensin II type 2-receptor gene polymorphism (-1332 G/A) in a cohort of 509 families with premature coronary artery disease.

  2005cites this paper
• A novel mutation of COL2A1 resulting in dominantly inherited rhegmatogenous retinal detachment.

  2005cites this paper
• Identification of the scaramanga gene implicates Neuregulin3 in mammary gland specification.

  2005cites this paper
• A Novel Mutation of COL 2 A 1 Resulting in Dominantly Inherited Rhegmatogenous Retinal Detachment

  2005cites this paper
• Intragenic modifiers of hereditary spastic paraplegia due to spastin gene mutations

  2004cites this paper
• Pharmacologic therapy for stop mutations: how much CFTR activity is enough?

  2004cites this paper
• Quantitative methods for the analysis of CFTR transcripts/splicing variants.

  2004cites this paper
• The Mutation Spectrum of the CFTR Gene in Cystic Fibrosis Patients from Bashkortostan

  2004cites this paper
• 1029-184 The clinical significance of a common, functional, X-linked angiotensin II type 2-receptor gene polymorphism (-1322 G/A) in a cohort of 509 families with premature coronary artery disease

  2004cites this paper
• Alternative splicing in disease and therapy

  2004cites this paper
• Traveling stripes on the skin of a mutant mouse

  2003cites this paper
• Molekulargenetische Grundlagen der zystischen Fibrose als Beispiel genetischer Erkrankungen in der Pneumologie

  2003cites this paper
• The Phenotypic Consequences of CFTR Mutations

  2003cites this paper
• [Molecular genetics principles in cystic fibrosis. An example of genetic illness in pneumology].

  2003cites this paper
• CFTR genotypes in patients with normal or borderline sweat chloride levels

  2003cites this paper
• New type of disease causing mutations: the example of the composite exonic regulatory elements of splicing in CFTR exon 12.

  2003cites this paper
• Characterization of disease-associated mutations affecting an exonic splicing enhancer and two cryptic splice sites in exon 13 of the cystic fibrosis transmembrane conductance regulator gene.

  2003cites this paper
• Molecular and pathological effects of a modifier gene on deficiency of the sodium channel Scn8a (Na(v)1.6).

  2002cites this paper
• Molecular diagnosis of cystic fibrosis

  2002cites this paper
• [Genetic diagnosis and consultation in bronchiectasia. First diagnosis of cystic fibrosis in an adult].

  2002cites this paper
• Splicing regulation as a potential genetic modifier.

  2002cites this paper
• Genetische Diagnostik und Beratung bei Bronchiektasien

  2002cites this paper
• Residual cftr Expression Varies with Age in cftrtm1Hgu Cystic Fibrosis Mice: Impact on Morphology and Physiology

  2002cites this paper
• Mucopolysaccharidosis type II – genotype/phenotype aspects

  2002cites this paper
• Quantification of NF1 transcripts reveals novel highly expressed splice variants

  2002cites this paper
• Survey of CF mutations in the clinical laboratory

  2002cites this paper
• Alternative splicing and expressivity of the AxinFu allele in mice

  2001cites this paper
• A novel 3600+11.5 kb C>G homozygous splicing mutation in a black African, consanguineous CF family

  2001cites this paper
• Alternative splicing and expressivity of the Axin(Fu) allele in mice.

  2001cites this paper
• Qualitative and quantitative analysis of mRNA associated with four putative splicing mutations (621+3A→G, 2751+2T→A, 296+1G→C, 1717–9T→C-D565G) and one nonsense mutation (E822X) in the CFTR gene

  2001cites this paper
• Niemann-Pick disease type C: spectrum of HE1 mutations and genotype/phenotype correlations in the NPC2 group.

  2001cites this paper
• Cellular and viral splicing factors can modify the splicing pattern of CFTR transcripts carrying splicing mutations.

  2000cites this paper
• A pilot study of the effect of gentamicin on nasal potential difference measurements in cystic fibrosis patients carrying stop mutations.

  2000cites this paper
• Three different premature stop codons lead to skipping of exon 7 in neurofibromatosis type I patients

  2000cites this paper
• Mutations affecting mRNA splicing are the most common molecular defects in patients with neurofibromatosis type 1.

  2000cites this paper
• Type I, II, III, IV, and V cystic fibrosis transmembrane conductance regulator defects and opportunities for therapy

  2000cites this paper
• Prolonged Survival in Hereditary Surfactant Protein B (SP-B) Deficiency Associated with a Novel Splicing Mutation

  2000cites this paper
• RPGR transcription studies in mouse and human tissues reveal a retina-specific isoform that is disrupted in a patient with X-linked retinitis pigmentosa.

  1999cites this paper
• Molecular Evolution: Towards the Origin of Metazoa

  1998cites this paper
• List of papers

  1995cites this paper
• Mutations in a single gene cause the entire CF clinical spectrum, ranging from classic chronic sinopulmonary disease with exocrine pancreatic insufficiency to single organ abnormalities such as electrolyte imbalances [2•], pancreatitis [10,11•,12•], liver disease [13•], sinusitis [14], and obstructi

  year unknowncites this paper